Immatics (IMTX) Other Non-Current Assets (2019 - 2025)
Immatics recorded quarterly Other Non-Current Assets of $2.2 million in Q4 2025, up 124.64% quarter-over-quarter from $958625.2 in Q3 2025, and up 61.22% year-over-year from $1.3 million in Q4 2024.
Immatics' Other Non-Current Assets history runs 7 years deep, the most recent figure standing at $2.2 million for Q4 2025.
- In Q4 2025, Other Non-Current Assets rose 61.22% year-over-year to $2.2 million; the TTM figure through Dec 2025 stood at $2.2 million (up 61.22% YoY), while the FY2025 annual figure was $2.1 million, up 56.48% from the prior year.
- Other Non-Current Assets came in at $2.2 million for Q4 2025 at Immatics, up from $958625.2 in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $5.0 million in Q2 2022 to a low of $710473.1 in Q1 2021.
- A 5-year average of $1.8 million and a median of $1.4 million in 2024 frame the typical range for Other Non-Current Assets.
- Across the five-year window, Other Non-Current Assets soared 390.53% in 2022 and tumbled 56.98% in 2023, its largest moves.
- Immatics' Other Non-Current Assets stood at $727565.5 in 2021, then jumped by 256.88% to $2.6 million in 2022, then dropped by 16.42% to $2.2 million in 2023, then plunged by 38.45% to $1.3 million in 2024, then jumped by 61.22% to $2.2 million in 2025.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $2.2 million, $958625.2, and $1.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 12.40 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 60,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.26 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 2.13 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 63.55 Mn |
| 10 | Immatics | 1.80 Bn | 1.80 Bn | - | 2.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.15 Mn |
| Sep 30, 2025 | 958,625.17 |
| Jun 30, 2025 | 1.13 Mn |
| Mar 31, 2025 | 1.19 Mn |
| Dec 31, 2024 | 1.34 Mn |
| Sep 30, 2024 | 1.32 Mn |
| Jun 30, 2024 | 1.44 Mn |
| Mar 31, 2024 | 1.49 Mn |
| Dec 31, 2023 | 2.17 Mn |
| Sep 30, 2023 | 1.81 Mn |
| Jun 30, 2023 | 2.15 Mn |
| Mar 31, 2023 | 2.43 Mn |
| Dec 31, 2022 | 2.60 Mn |
| Sep 30, 2022 | 4.05 Mn |
| Jun 30, 2022 | 4.99 Mn |
| Mar 31, 2022 | 986,534.85 |
| Dec 31, 2021 | 727,565.52 |
| Sep 30, 2021 | 847,907.58 |
| Jun 30, 2021 | 1.02 Mn |
| Mar 31, 2021 | 710,473.07 |
| Dec 31, 2020 | 863,217.85 |
| Sep 30, 2020 | 738,224.81 |
| Jun 30, 2020 | 766,616.25 |
| Dec 31, 2019 | 1.40 Mn |